Alexion Pharmaceuticals

Alexion Pharmaceuticals
legal form	Corporation
ISIN	US0153511094
founding	1992
Seat	Boston , Massachusetts
management	Ludwig Hantson (CEO)
Number of employees	approx. 2,500
sales	5.0 billion US dollars (2019)
Branch	Pharmaceutical Industry
Website	www.alxn.com

Alexion Pharmaceuticals is a biopharmaceutical company based in Boston . Alexion is traded on the NASDAQ and is listed on the NASDAQ-100 . The company specializes in orphan drugs for the treatment of rare and very rare diseases.

history

Alexion was founded in 1992 by Leonard Bell , a professor of internal medicine and pathology at Yale University, among others . In 2011, Alexion took over Taligen Therapeutics ( Cambridge , Massachusetts ) and founded the Translational Medicine Group to bring new product candidates to clinical trials faster . Also in 2011, Alexion acquired Enobia Pharma ( Montreal , Canada ) and its rights to Asfotase Alpha , a product candidate for the treatment of hypophosphatasia . In 2018, the company relocated its headquarters from New Haven , Connecticut, to Boston.

Key figures

In 2019, the company had $ 4.99 billion in revenue, almost entirely from Soliris ($ 3.9 billion). Alexion has more than 50 offices including Tokyo , Sydney , Zurich and Munich and employs around 2,500 people worldwide.

Medication

• Soliris ( eculizumab ) is used for treatment
  • of paroxysmal nocturnal hemoglobinuria (PNH)
  • of atypical hemolytic uremic syndrome (aHUS) and
  • the refractory AChR AK-positive generalized myasthenia gravis (refractory GMG)

• Ultomiris ( ravulizumab ) is the first and only approved long-acting C5 complement inhibitor for the treatment of PNH.

pipeline

• Eculizumab is used in numerous other indications (Antibody Mediated Rejection (AMR) - Living and Deceased Donor, Delayed Graft Function (DGF), Relapsing Neuromyelitis Optica (NMO), Severe and Refractory Myasthenia Gravis (MG), Shiga-toxin E. coli-related (STEC) HUS).
• Asfotase Alfa - orphan drug status - is approved for the indication hypophosphatasia .
• ALXN1101 to treat molybdenum cofactor deficiency (MOCD) Type A .
• ALXN1007 - Anti-inflammatory Antibody.
• ALXN1102 / 1103 - Anti-Complement.

Web links

• alxn.com - Alexion Pharmaceuticals
• In focus: Alexion Pharmaceuticals. Doctors newspaper of June 12, 2012

Individual evidence

1. ↑ ^{a b c} Alexion: Alexion Global Presence . 2020. Accessed February 5, 2020.
2. ↑ Alexion: Alexion Leadership . 2019. Retrieved February 7, 2019.
3. ↑ ^{a b} Alexion: Alexion Press Release . January 30, 2020. Accessed February 5, 2020.
4. ↑ USA Today: Alexion Pharmaceuticals Inc. moving headquarters to Boston . September 12, 2017. Retrieved April 19, 2019.
5. ↑ ^{a b c d e} Alexion: Pipeline , accessed from the international website on April 22, 2014